Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Public antigenic determinant on a family of HLA-B molecules.
B D Schwartz, … , L K Luehrman, G E Rodey
B D Schwartz, … , L K Luehrman, G E Rodey
Published October 1, 1979
Citation Information: J Clin Invest. 1979;64(4):938-947. https://doi.org/10.1172/JCI109560.
View: Text | PDF
Research Article

Public antigenic determinant on a family of HLA-B molecules.

  • Text
  • PDF
Abstract

Serologic cross-reactivity among allelic gene products commonly occurs in the HLA complex, but the molecular basis of these serologic phenomena is incompletely characterized. Because of strong cross-reactivity among antigens comprising the B7 cross-reactive group (i.e., HLA-B7, Bw22, B27, B40, and Bw42) and because of the association of several antigens of this group with spondyloarthropathies, we initiated a study of the chemical basis of cross-reactivity among this group of antigens. Using classic serologic procedures, 125I-Protein A binding assay, and chemical immunoprecipitation techniques, we have defined a new antigenic determinant, tentatively designated "X", which is present on certain HLA-B molecules. By a series of sequential immunoprecipitation experiments, X was shown to be a "public" antigenic determinant distinct from the "private" determinants B7, Bw22, B27, and B40, but present on the same 44,000-dalton glycoprotein molecules. The implications of this finding regarding disease predisposition and HLA typing as a diagnostic aid are discussed.

Authors

B D Schwartz, L K Luehrman, G E Rodey

×

Full Text PDF | Download (1.52 MB)


Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts